Invivyd (IVVD) EPS (Weighted Average and Diluted) (2021 - 2025)
Invivyd posted quarterly EPS (Weighted Average and Diluted) of -$0.07 for Q4 2025, up 51.4% year-on-year from -$0.05 in Q4 2024, and down 21.51% on a QoQ basis from -$0.06 in Q3 2025.
Invivyd (IVVD) has 5 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.07 in Q4 2025.
- For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 51.4% year-over-year to -$0.07; the trailing twelve-month figure through Dec 2025 stood at -$0.32 (up 77.78% YoY), and the FY2025 full-year result was -$0.3, up 79.02% from the prior year.
- EPS (Weighted Average and Diluted) for Q4 2025 stood at -$0.07, down from -$0.06 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $1.74 in Q4 2021 and bottomed at -$178.86 in Q2 2021.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.4 (2024), against an average of -$9.68.
- Peak annual rise in EPS (Weighted Average and Diluted) reached 99.74% in 2022, while the deepest fall reached 123.56% in 2022.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $1.74 in 2021, then tumbled by 123.56% to -$0.41 in 2022, then slumped by 63.41% to -$0.67 in 2023, then jumped by 77.61% to -$0.15 in 2024, then soared by 51.4% to -$0.07 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.07 (Q4 2025), -$0.06 (Q3 2025), and -$0.12 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - | -0.07 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.07 |
| Sep 30, 2025 | -0.06 |
| Jun 30, 2025 | -0.12 |
| Mar 31, 2025 | -0.14 |
| Dec 31, 2024 | -0.15 |
| Sep 30, 2024 | -0.51 |
| Jun 30, 2024 | -0.40 |
| Mar 31, 2024 | -0.38 |
| Dec 31, 2023 | -0.67 |
| Sep 30, 2023 | -0.36 |
| Jun 30, 2023 | -0.46 |
| Mar 31, 2023 | -0.32 |
| Dec 31, 2022 | -0.41 |
| Sep 30, 2022 | -0.42 |
| Jun 30, 2022 | -0.47 |
| Mar 31, 2022 | -0.93 |
| Dec 31, 2021 | 1.74 |
| Sep 30, 2021 | -0.98 |
| Jun 30, 2021 | -178.86 |